

State of Arizona
House of Representatives
Fifty-first Legislature
Second Regular Session
2014

CHAPTER 255

HOUSE BILL 2078

AN ACT

AMENDING TITLE 20, CHAPTER 4, ARTICLE 3, ARIZONA REVISED STATUTES, BY ADDING SECTION 20-841.10; AMENDING TITLE 20, CHAPTER 4, ARTICLE 9, ARIZONA REVISED STATUTES, BY ADDING SECTION 20-1057.14; AMENDING TITLE 20, CHAPTER 6, ARTICLE 4, ARIZONA REVISED STATUTES, BY ADDING SECTION 20-1376.05; AMENDING TITLE 20, CHAPTER 6, ARTICLE 5, ARIZONA REVISED STATUTES, BY ADDING SECTION 20-1406.06; RELATING TO HEALTH INSURANCE.

(TEXT OF BILL BEGINS ON NEXT PAGE)

1 Be it enacted by the Legislature of the State of Arizona:

2 Section 1. Title 20, chapter 4, article 3, Arizona Revised Statutes,
3 is amended by adding section 20-841.10, to read:

4 20-841.10. Cancer treatment medications; cost-sharing;
5 definition

6 A. A CONTRACT THAT IS ISSUED, DELIVERED OR RENEWED BY A CORPORATION ON
7 OR AFTER JANUARY 1, 2016 AND THAT PROVIDES COVERAGE BOTH FOR CANCER TREATMENT
8 MEDICATIONS THAT ARE INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE
9 PROVIDER AND FOR PATIENT-ADMINISTERED CANCER TREATMENT MEDICATIONS, INCLUDING
10 MEDICATIONS THAT ARE ORALLY ADMINISTERED OR SELF-INJECTED, MAY NOT REQUIRE A
11 HIGHER COPAYMENT, DEDUCTIBLE OR COINSURANCE AMOUNT FOR PATIENT-ADMINISTERED
12 CANCER TREATMENT MEDICATIONS THAN IS REQUIRED FOR THOSE CANCER TREATMENT
13 MEDICATIONS THAT ARE INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE
14 PROVIDER, REGARDLESS OF THE FORMULATION OR BENEFIT CATEGORY.

15 B. A CORPORATION MAY NOT INCREASE COPAYMENT, DEDUCTIBLE OR COINSURANCE
16 AMOUNTS FOR COVERED CANCER TREATMENT MEDICATIONS THAT ARE INJECTED OR
17 INTRAVENOUSLY ADMINISTERED IN ORDER TO AVOID COMPLIANCE WITH SUBSECTION A OF
18 THIS SECTION, BUT MAY INCREASE COPAYMENT, DEDUCTIBLE OR COINSURANCE AMOUNTS
19 FOR CANCER TREATMENT MEDICATIONS IF THE INCREASE IS APPLIED GENERALLY TO
20 OTHER MEDICAL OR PHARMACEUTICAL BENEFITS UNDER THE CONTRACT AND IS NOT DONE
21 TO CIRCUMVENT SUBSECTION A OF THIS SECTION.

22 C. A CORPORATION MAY NOT RECLASSIFY BENEFITS WITH RESPECT TO CANCER
23 TREATMENT MEDICATIONS IN A MANNER THAT IS INCONSISTENT WITH THIS SECTION.

24 D. FOR THE PURPOSES OF THIS SECTION, "CANCER TREATMENT MEDICATIONS"
25 MEANS PRESCRIPTION DRUGS AND BIOLOGICS THAT ARE USED TO KILL, SLOW OR PREVENT
26 THE GROWTH OF CANCEROUS CELLS.

27 Sec. 2. Title 20, chapter 4, article 9, Arizona Revised Statutes, is
28 amended by adding section 20-1057.14, to read:

29 20-1057.14. Cancer treatment medications; cost-sharing;
30 definition

31 A. AN EVIDENCE OF COVERAGE THAT IS ISSUED, DELIVERED OR RENEWED BY A
32 HEALTH CARE SERVICES ORGANIZATION ON OR AFTER JANUARY 1, 2016 AND THAT
33 PROVIDES COVERAGE BOTH FOR CANCER TREATMENT MEDICATIONS THAT ARE INJECTED OR
34 INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER AND FOR
35 PATIENT-ADMINISTERED CANCER TREATMENT MEDICATIONS, INCLUDING MEDICATIONS THAT
36 ARE ORALLY ADMINISTERED OR SELF-INJECTED, MAY NOT REQUIRE A HIGHER COPAYMENT,
37 DEDUCTIBLE OR COINSURANCE AMOUNT FOR PATIENT-ADMINISTERED CANCER TREATMENT
38 MEDICATIONS THAN IS REQUIRED FOR THOSE CANCER TREATMENT MEDICATIONS THAT ARE
39 INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER, REGARDLESS
40 OF THE FORMULATION OR BENEFIT CATEGORY.

41 B. A HEALTH CARE SERVICES ORGANIZATION MAY NOT INCREASE COPAYMENT,
42 DEDUCTIBLE OR COINSURANCE AMOUNTS FOR COVERED CANCER TREATMENT MEDICATIONS
43 THAT ARE INJECTED OR INTRAVENOUSLY ADMINISTERED IN ORDER TO AVOID COMPLIANCE
44 WITH SUBSECTION A OF THIS SECTION, BUT MAY INCREASE COPAYMENT, DEDUCTIBLE OR
45 COINSURANCE AMOUNTS FOR CANCER TREATMENT MEDICATIONS IF THE INCREASE IS
46 APPLIED GENERALLY TO OTHER MEDICAL OR PHARMACEUTICAL BENEFITS UNDER THE

1 EVIDENCE OF COVERAGE AND IS NOT DONE TO CIRCUMVENT SUBSECTION A OF THIS
2 SECTION.

3 C. A HEALTH CARE SERVICES ORGANIZATION MAY NOT RECLASSIFY BENEFITS
4 WITH RESPECT TO CANCER TREATMENT MEDICATIONS IN A MANNER THAT IS INCONSISTENT
5 WITH THIS SECTION.

6 D. FOR THE PURPOSES OF THIS SECTION, "CANCER TREATMENT MEDICATIONS"
7 MEANS PRESCRIPTION DRUGS AND BIOLOGICS THAT ARE USED TO KILL, SLOW OR PREVENT
8 THE GROWTH OF CANCEROUS CELLS.

9 Sec. 3. Title 20, chapter 6, article 4, Arizona Revised Statutes, is
10 amended by adding section 20-1376.05, to read:

11 20-1376.05. Cancer treatment medications; cost-sharing;
12 definition

13 A. A DISABILITY INSURANCE POLICY THAT IS ISSUED, DELIVERED OR RENEWED
14 BY A DISABILITY INSURER ON OR AFTER JANUARY 1, 2016 AND THAT PROVIDES
15 COVERAGE BOTH FOR CANCER TREATMENT MEDICATIONS THAT ARE INJECTED OR
16 INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER AND FOR
17 PATIENT-ADMINISTERED CANCER TREATMENT MEDICATIONS, INCLUDING MEDICATIONS THAT
18 ARE ORALLY ADMINISTERED OR SELF-INJECTED, MAY NOT REQUIRE A HIGHER COPAYMENT,
19 DEDUCTIBLE OR COINSURANCE AMOUNT FOR PATIENT-ADMINISTERED CANCER TREATMENT
20 MEDICATIONS THAN IS REQUIRED FOR THOSE CANCER TREATMENT MEDICATIONS THAT ARE
21 INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER, REGARDLESS
22 OF THE FORMULATION OR BENEFIT CATEGORY.

23 B. A DISABILITY INSURER MAY NOT INCREASE COPAYMENT, DEDUCTIBLE OR
24 COINSURANCE AMOUNTS FOR COVERED CANCER TREATMENT MEDICATIONS THAT ARE
25 INJECTED OR INTRAVENOUSLY ADMINISTERED IN ORDER TO AVOID COMPLIANCE WITH
26 SUBSECTION A OF THIS SECTION, BUT MAY INCREASE COPAYMENT, DEDUCTIBLE OR
27 COINSURANCE AMOUNTS FOR CANCER TREATMENT MEDICATIONS IF THE INCREASE IS
28 APPLIED GENERALLY TO OTHER MEDICAL OR PHARMACEUTICAL BENEFITS UNDER THE
29 POLICY AND IS NOT DONE TO CIRCUMVENT SUBSECTION A OF THIS SECTION.

30 C. A DISABILITY INSURER MAY NOT RECLASSIFY BENEFITS WITH RESPECT TO
31 CANCER TREATMENT MEDICATIONS IN A MANNER THAT IS INCONSISTENT WITH THIS
32 SECTION.

33 D. FOR THE PURPOSES OF THIS SECTION, "CANCER TREATMENT MEDICATIONS"
34 MEANS PRESCRIPTION DRUGS AND BIOLOGICS THAT ARE USED TO KILL, SLOW OR PREVENT
35 THE GROWTH OF CANCEROUS CELLS.

36 Sec. 4. Title 20, chapter 6, article 5, Arizona Revised Statutes, is
37 amended by adding section 20-1406.06, to read:

38 20-1406.06. Cancer treatment medications; cost-sharing;
39 definition

40 A. A GROUP OR BLANKET DISABILITY POLICY THAT IS ISSUED, DELIVERED OR
41 RENEWED BY A GROUP OR BLANKET DISABILITY INSURER ON OR AFTER JANUARY 1, 2016
42 AND THAT PROVIDES COVERAGE BOTH FOR CANCER TREATMENT MEDICATIONS THAT ARE
43 INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER AND FOR
44 PATIENT-ADMINISTERED CANCER TREATMENT MEDICATIONS, INCLUDING MEDICATIONS THAT
45 ARE ORALLY ADMINISTERED OR SELF-INJECTED, MAY NOT REQUIRE A HIGHER COPAYMENT,
46 DEDUCTIBLE OR COINSURANCE AMOUNT FOR PATIENT-ADMINISTERED CANCER TREATMENT

1 MEDICATIONS THAN IS REQUIRED FOR THOSE CANCER TREATMENT MEDICATIONS THAT ARE
2 INJECTED OR INTRAVENOUSLY ADMINISTERED BY A HEALTH CARE PROVIDER, REGARDLESS
3 OF THE FORMULATION OR BENEFIT CATEGORY.

4 B. A GROUP OR BLANKET DISABILITY INSURER MAY NOT INCREASE COPAYMENT,
5 DEDUCTIBLE OR COINSURANCE AMOUNTS FOR COVERED CANCER TREATMENT MEDICATIONS
6 THAT ARE INJECTED OR INTRAVENOUSLY ADMINISTERED IN ORDER TO AVOID COMPLIANCE
7 WITH SUBSECTION A OF THIS SECTION, BUT MAY INCREASE COPAYMENT, DEDUCTIBLE OR
8 COINSURANCE AMOUNTS FOR CANCER TREATMENT MEDICATIONS IF THE INCREASE IS
9 APPLIED GENERALLY TO OTHER MEDICAL OR PHARMACEUTICAL BENEFITS UNDER THE
10 POLICY AND IS NOT DONE TO CIRCUMVENT SUBSECTION A OF THIS SECTION.

11 C. A GROUP OR BLANKET DISABILITY INSURER MAY NOT RECLASSIFY BENEFITS
12 WITH RESPECT TO CANCER TREATMENT MEDICATIONS IN A MANNER THAT IS INCONSISTENT
13 WITH THIS SECTION.

14 D. FOR THE PURPOSES OF THIS SECTION, "CANCER TREATMENT MEDICATIONS"
15 MEANS PRESCRIPTION DRUGS AND BIOLOGICS THAT ARE USED TO KILL, SLOW OR PREVENT
16 THE GROWTH OF CANCEROUS CELLS.

17 Sec. 5. Short title

18 This act may be cited as the "Fair Access to Cancer Treatment Act".

APPROVED BY THE GOVERNOR MAY 30, 2014.

FILED IN THE OFFICE OF THE SECRETARY OF STATE MAY 30, 2014.